These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 11176382

  • 1. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D, Höltl W, Bassi P, Brausi M, Ferrari P, de Balincourt C, Sylvester R, European Organization for Research and Treatment of Cancer Genitourinary Group.
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [Abstract] [Full Text] [Related]

  • 2. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 3. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 4. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A.
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [Abstract] [Full Text] [Related]

  • 5. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, Leimert JT, Crawford ED.
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [Abstract] [Full Text] [Related]

  • 6. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer.
    Guevara A, Salomon L, Allory Y, Ploussard G, de la Taille A, Paul A, Yiou R, Hoznek A, Dahan M, Abbou CC, Vordos D.
    J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454
    [Abstract] [Full Text] [Related]

  • 7. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 8. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 9. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response.
    van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, Barten EJ, Puri R, van Kalken CK, Witjes JA.
    J Urol; 2006 Oct 15; 176(4 Pt 1):1349-53; discussion 1353. PubMed ID: 16952629
    [Abstract] [Full Text] [Related]

  • 10. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D, Situm M, Eterovic D, Dogas Z, Gotovac J.
    Croat Med J; 2003 Apr 15; 44(2):187-92. PubMed ID: 12698510
    [Abstract] [Full Text] [Related]

  • 11. Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review.
    Cheng CW, Ng MT, Chan SY, Sun WH.
    ANZ J Surg; 2004 Jul 15; 74(7):569-72. PubMed ID: 15230793
    [Abstract] [Full Text] [Related]

  • 12. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
    de Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, Landsoght KE, Carpentier P, European Organization for the Research and Treatment of Cancer-Genito-Urinary Group.
    J Urol; 2005 Feb 15; 173(2):405-9. PubMed ID: 15643181
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer.
    Okamura T, Tozawa K, Yamada Y, Sakagami H, Ueda K, Kohri K.
    J Urol; 1996 Sep 15; 156(3):967-71. PubMed ID: 8709375
    [Abstract] [Full Text] [Related]

  • 14. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M, Guerin F, Amsellem-Ouazana D, Saighi D, Debre B, Zerbib M.
    J Urol; 2003 Jun 15; 169(6):2110-2. PubMed ID: 12771729
    [Abstract] [Full Text] [Related]

  • 15. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar 15; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 16. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP, Hall RR, Macaluso MP, Pawinsky A, Sylvester R, Van Glabbeke M.
    Eur Urol; 1996 Mar 15; 29(2):199-203. PubMed ID: 8647147
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug 15; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 18. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
    Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM.
    J Urol; 2008 Oct 15; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
    [Abstract] [Full Text] [Related]

  • 19. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A, Yonou H, Hayashi E, Iha K, Oda M, Miyazato M, Oshiro Y, Hokama S, Sugaya K, Ogawa Y.
    Urology; 2007 Feb 15; 69(2):275-9. PubMed ID: 17320663
    [Abstract] [Full Text] [Related]

  • 20. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH, Ye G, Wang XW, Jin HS, Zhang YN, Yan ZL.
    Ai Zheng; 2008 Nov 15; 27(11):1208-11. PubMed ID: 19000455
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.